RxDoctor Payments Data

William Mitchell, MD

Urology · Mc Kinney, TXNPI 1689672271

Payments from drug & device makers

$6,180in general payments, 2019–2025

Across 268 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Agiliti Surgical, Inc.$833
  • Boston Scientific$587
  • Pfizer$512
  • Astellas Pharma US Inc$491
  • AbbVie$424
  • Endo Pharmaceuticals Inc.$284
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$6,04298%
  • Education$1382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,180 in reported general payments places this provider in the 60th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$172,568
Medicare patients
494
Services billed
2,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron117$97,351
GemtesaVibegron65$44,481
Alfuzosin Hcl ErAlfuzosin Hcl358$7,796
Tamsulosin Hcl481$6,578
Finasteride312$3,703
Potassium Citrate ErPotassium Citrate53$3,476
Dutasteride42$1,742
NitrofurantoinNitrofurantoin Macrocrystal55$1,447
Testosterone15$1,171
CefuroximeCefuroxime Axetil25$448
Oxybutynin Chloride ErOxybutynin Chloride37$421
Solifenacin Succinate14$395
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip23$272
Allopurinol28$249
Ciprofloxacin Hcl21$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$491$97,351117 claims
Sumitomo Pharma America, Inc.Gemtesa$155$44,48165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 878 urology providers in Texas.

Other urology in Mc Kinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →